 Continuous infusion carboplatin schedule phase pharmacokinetic study phase continuous infusion carboplatin days weeks venous access port portable pump dose range increments Forty-four patients courses median range World Health Organization WHO III/IV leukopenia thrombocytopenia patients patients Cumulative platelet depression dose levels Median glomerular filtration rate GFR effective renal plasma flow radioisotope clearances doses equal courses relationship percentage platelet depression GFR toxicity patients evaluable complete response partial responses addition patients stable disease Pharmacokinetic analysis total ultrafiltrable platinum UFPt atomic absorption spectrophotometry Steady-state plasma levels UFPt hours levels dose steady state carboplatin dose UFPt plasma levels steady-state UFPt GFR Twenty-four percent total platinum Pt present UFPt steady state micrograms/L Total body clearance UFPt GFR times Mean area curve AUC UFPt continuous infusion mg.min/L total Pt steady-state plasma levels total Pt plasma levels day day significant relation total Pt serum levels day drug dose Immunohistochemical analysis DNA-bound Pt leukocytes linear increase day day day DNA-bound Pt duration infusion individual patients maximum-tolerable dose carboplatin days total phase II studies